A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

This study tests two investigational therapies — BL-B01D1 (an antibody-drug conjugate) and SI-B003 (an immunotherapy) — alone and in combination, in women with recurrent or metastatic cervical cancer and other gynecological cancers that have not responded to standard treatment. **You may be eligible if...** - You are a woman between 18 and 75 years old - You have a confirmed diagnosis of recurrent or metastatic cervical cancer or another gynecological malignancy - Your cancer has failed or you cannot tolerate standard treatments - Your expected survival is at least 3 months and you have good physical function (ECOG 0-1) **You may NOT be eligible if...** - You are outside the 18-75 age range - Your gynecological cancer has not been confirmed by pathology - Your overall health is too poor to tolerate investigational treatment Talk to your doctor to see if this trial is right for you.